KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $9.2 million.

  • Arbutus Biopharma's Operating Expenses fell 5966.46% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year decrease of 3167.29%. This contributed to the annual value of $82.5 million for FY2024, which is 1429.08% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Operating Expenses of $9.2 million as of Q3 2025, which was down 5966.46% from $9.3 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Operating Expenses high stood at $28.8 million for Q4 2022, and its period low was $9.2 million during Q3 2025.
  • Moreover, its 5-year median value for Operating Expenses was $23.0 million (2023), whereas its average is $21.8 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 4309.79% in 2021, then plummeted by 6031.15% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Operating Expenses (Quarter) stood at $24.0 million in 2021, then increased by 20.02% to $28.8 million in 2022, then fell by 20.53% to $22.9 million in 2023, then plummeted by 32.26% to $15.5 million in 2024, then crashed by 40.75% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $9.3 million for Q2 2025, and $27.5 million during Q1 2025.